GSK lays out Japan launch plans
This article was originally published in Scrip
GlaxoSmithKline is anticipating the approval of three new molecular entities (NMEs) in Japan this calendar year, the same number it received in 2013, with the biggest commercial opportunity in patient number terms being the combination therapy for chronic obstructive pulmonary disease (COPD) umeclidinium plus vilanterol.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.